| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Peripheral-blood stem cells versus bone marrow from unrelated donors.
|
N Engl J Med
|
2012
|
6.30
|
|
2
|
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
|
J Clin Oncol
|
2013
|
3.77
|
|
3
|
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
Blood
|
2011
|
3.41
|
|
4
|
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
|
J Clin Oncol
|
2010
|
2.99
|
|
5
|
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
|
Blood
|
2008
|
2.34
|
|
6
|
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
|
Blood
|
2010
|
2.16
|
|
7
|
Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen.
|
J Immunol
|
2012
|
1.98
|
|
8
|
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
|
Blood
|
2005
|
1.95
|
|
9
|
Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program.
|
Biol Blood Marrow Transplant
|
2007
|
1.89
|
|
10
|
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
1.88
|
|
11
|
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.
|
Biol Blood Marrow Transplant
|
2011
|
1.88
|
|
12
|
Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model.
|
Am J Pathol
|
2002
|
1.80
|
|
13
|
One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.
|
Biol Blood Marrow Transplant
|
2010
|
1.69
|
|
14
|
Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing.
|
Cytotherapy
|
2011
|
1.65
|
|
15
|
NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions.
|
Blood
|
2011
|
1.62
|
|
16
|
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
|
J Clin Oncol
|
2013
|
1.59
|
|
17
|
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
|
Blood
|
2013
|
1.54
|
|
18
|
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.
|
Blood
|
2012
|
1.51
|
|
19
|
CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent.
|
Am Heart J
|
2011
|
1.47
|
|
20
|
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma.
|
Leuk Lymphoma
|
2014
|
1.42
|
|
21
|
PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.
|
J Clin Invest
|
2009
|
1.37
|
|
22
|
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
|
J Immunother
|
2009
|
1.36
|
|
23
|
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
|
Clin Cancer Res
|
2010
|
1.29
|
|
24
|
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
|
Blood
|
2013
|
1.27
|
|
25
|
Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor.
|
J Virol
|
2005
|
1.27
|
|
26
|
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
|
Blood
|
2012
|
1.23
|
|
27
|
Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation.
|
Blood
|
2014
|
1.20
|
|
28
|
Autoimmune neutropenia in adults.
|
Autoimmun Rev
|
2009
|
1.10
|
|
29
|
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
|
Immunotherapy
|
2009
|
1.07
|
|
30
|
IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
|
Blood
|
2011
|
1.02
|
|
31
|
Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation.
|
Blood
|
2002
|
1.02
|
|
32
|
Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia.
|
Biol Blood Marrow Transplant
|
2010
|
1.01
|
|
33
|
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
|
Transfusion
|
2011
|
1.01
|
|
34
|
Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease.
|
Am Heart J
|
2009
|
1.01
|
|
35
|
Translational applications of flow cytometry in clinical practice.
|
J Immunol
|
2012
|
1.00
|
|
36
|
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
|
Blood
|
2005
|
1.00
|
|
37
|
Dichotomous role of interferon-gamma in allogeneic bone marrow transplant.
|
Biol Blood Marrow Transplant
|
2009
|
0.97
|
|
38
|
Chronic GvHD decreases antiviral immune responses in allogeneic BMT.
|
Blood
|
2007
|
0.96
|
|
39
|
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2014
|
0.95
|
|
40
|
Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms.
|
Mod Pathol
|
2006
|
0.94
|
|
41
|
Peripheral blood mononuclear cells acquire myofibroblast characteristics in granulation tissue.
|
J Vasc Res
|
2005
|
0.94
|
|
42
|
Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.
|
J Immunol
|
2011
|
0.93
|
|
43
|
Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation.
|
J Immunol
|
2009
|
0.93
|
|
44
|
Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
|
Biol Blood Marrow Transplant
|
2007
|
0.93
|
|
45
|
Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
|
Biol Blood Marrow Transplant
|
2013
|
0.93
|
|
46
|
In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.
|
Biol Blood Marrow Transplant
|
2013
|
0.93
|
|
47
|
Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (≤1500 g) using cytomegalovirus-seronegative and leukoreduced transfusions.
|
Transfus Med Rev
|
2011
|
0.93
|
|
48
|
A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
|
Blood
|
2002
|
0.92
|
|
49
|
Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.
|
Biol Blood Marrow Transplant
|
2013
|
0.92
|
|
50
|
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
|
Cancer
|
2013
|
0.92
|
|
51
|
Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.91
|
|
52
|
The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy.
|
Biomaterials
|
2013
|
0.91
|
|
53
|
Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice.
|
J Immunol
|
2011
|
0.91
|
|
54
|
Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
0.90
|
|
55
|
Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection.
|
J Immunol
|
2008
|
0.90
|
|
56
|
Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
|
Biol Blood Marrow Transplant
|
2003
|
0.89
|
|
57
|
Providing personalized prognostic information for adult leukemia survivors.
|
Biol Blood Marrow Transplant
|
2013
|
0.89
|
|
58
|
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
|
Cancer
|
2006
|
0.89
|
|
59
|
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
|
Biol Blood Marrow Transplant
|
2004
|
0.88
|
|
60
|
Reconstructing immunity after allogeneic transplantation.
|
Immunol Res
|
2004
|
0.88
|
|
61
|
Monitoring blood for CD34+ cells to determine timing of Hematopoietic Progenitor Cells Apheresis.
|
Methods Mol Biol
|
2012
|
0.87
|
|
62
|
Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation.
|
J Immunol
|
2003
|
0.86
|
|
63
|
Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature.
|
Transfusion
|
2014
|
0.86
|
|
64
|
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.85
|
|
65
|
Finding the sweet spot for donor lymphocyte infusions.
|
Biol Blood Marrow Transplant
|
2013
|
0.83
|
|
66
|
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience.
|
Biol Blood Marrow Transplant
|
2007
|
0.82
|
|
67
|
Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients.
|
J Clin Apher
|
2014
|
0.82
|
|
68
|
Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients.
|
Blood
|
2013
|
0.82
|
|
69
|
Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.
|
Biol Blood Marrow Transplant
|
2013
|
0.81
|
|
70
|
Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
|
Biol Blood Marrow Transplant
|
2012
|
0.81
|
|
71
|
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
|
Biol Blood Marrow Transplant
|
2011
|
0.81
|
|
72
|
CD8-predominant T-cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxis.
|
Blood
|
2014
|
0.81
|
|
73
|
Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
0.80
|
|
74
|
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.
|
Transfusion
|
2010
|
0.80
|
|
75
|
Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.
|
Br J Haematol
|
2013
|
0.80
|
|
76
|
A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses.
|
Vaccine
|
2002
|
0.80
|
|
77
|
Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
|
Exp Hematol
|
2006
|
0.80
|
|
78
|
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study.
|
Leuk Lymphoma
|
2012
|
0.80
|
|
79
|
The regulation and activity of interleukin-12.
|
Front Biosci (Schol Ed)
|
2012
|
0.80
|
|
80
|
VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice.
|
PLoS One
|
2013
|
0.79
|
|
81
|
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
|
Leuk Lymphoma
|
2006
|
0.79
|
|
82
|
Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer.
|
Breast Cancer Res Treat
|
2015
|
0.79
|
|
83
|
Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
0.79
|
|
84
|
The yin and yang of adaptive immunity in allogeneic hematopoietic cell transplantation: donor antigen-presenting cells can either augment or inhibit donor T cell alloreactivity.
|
Adv Exp Med Biol
|
2007
|
0.79
|
|
85
|
Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
0.79
|
|
86
|
Treating chemotherapy-induced thrombocytopenia: is it time for oncologists to use thrombopoietin agonists?
|
Oncology (Williston Park)
|
2015
|
0.79
|
|
87
|
Properties of immature myeloid progenitors with nitric-oxide-dependent immunosuppressive activity isolated from bone marrow of tumor-free mice.
|
PLoS One
|
2013
|
0.79
|
|
88
|
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
0.78
|
|
89
|
CT2--the clinical trials control tower: overcoming barriers to opening oncology clinical trials.
|
J Clin Oncol
|
2007
|
0.78
|
|
90
|
The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
|
Exp Hematol
|
2002
|
0.78
|
|
91
|
Regulation of alloimmune responses by dendritic cell subsets.
|
Exp Hematol
|
2008
|
0.78
|
|
92
|
Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer.
|
Cancer Med
|
2014
|
0.78
|
|
93
|
Induction of human herpesvirus 8 gene expression in a posttransplantation primary effusion lymphoma cell line.
|
Leuk Lymphoma
|
2002
|
0.78
|
|
94
|
Signal transduction and myeloma: new targets, new hope.
|
Cancer Biol Ther
|
2003
|
0.78
|
|
95
|
Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.
|
Cancer
|
2013
|
0.78
|
|
96
|
Characterization of mechanical dyssynchrony measured by gated single photon emission computed tomography phase analysis after acute ST-elevation myocardial infarction.
|
J Nucl Cardiol
|
2011
|
0.77
|
|
97
|
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
|
Leuk Lymphoma
|
2014
|
0.77
|
|
98
|
New molecule for mobilizing marrow stem cells.
|
Blood
|
2014
|
0.77
|
|
99
|
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
|
Transfusion
|
2012
|
0.77
|
|
100
|
Proangiogenic cell colonies grown in vitro from human peripheral blood mononuclear cells.
|
J Biomol Screen
|
2012
|
0.76
|
|
101
|
Natural suppressor cells; past, present and future.
|
Front Biosci (Elite Ed)
|
2012
|
0.76
|
|
102
|
Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin.
|
Exp Hematol
|
2011
|
0.75
|
|
103
|
Birth order and transplantation outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow Transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
104
|
Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case report.
|
J Med Case Rep
|
2011
|
0.75
|
|
105
|
Evaluation of peripheral blood stem cell quality in products transported by traditional courier or commercial overnight shipping services.
|
Transfusion
|
2014
|
0.75
|
|
106
|
Hematopoietic Progenitor Cell Apheresis processing.
|
Methods Mol Biol
|
2012
|
0.75
|
|
107
|
Smudge cells following treatment with pentostatin in a patient with B-cell prolymphocytic leukemia.
|
Blood
|
2013
|
0.75
|
|
108
|
Howell-Jolly bodies in patients with chronic GVHD.
|
Blood
|
2009
|
0.75
|
|
109
|
Howell-Jolly body-like inclusions in neutrophils.
|
Blood
|
2009
|
0.75
|
|
110
|
Tools to optimize the functionality of a leukemia clinical trial team.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
111
|
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
|
Transfusion
|
2007
|
0.75
|
|
112
|
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
|
Transfusion
|
2011
|
0.75
|
|
113
|
Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
0.75
|